Patent intelligence · US
US 9295645
Compositions comprising buprenorphine
Compositions comprising buprenorphine
Patent details — US 9295645
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 29, 2016
- Expiration
- Mar 24, 2036
- Applicant
- Indivior UK Limited
- Claims
- 20
- CPC classes
- A61K, A61K31/439, A61K31/485, A61K47/10
Quick answer
US 9295645 (Compositions comprising buprenorphine) is held by Indivior UK Limited. Status: granted. Granted Mar 29, 2016. Expires Mar 24, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Indivior UK Limited
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/439, A61K31/485, A61K47/10, A61K47/26, A61K9/0019
More from Indivior UK Limited
Related pharmaceutical patents in our USPTO index.
-
US 12290596
Compositions and methods for the treatment of opioid overdose
granted -
US 11839611
Buprenorphine dosing regimens
granted -
US 11712475
Sustained delivery formulations of risperidone compound
granted -
US 11135216
Sublingual and buccal film compositions
granted -
US 11110093
Sustained release small molecule drug formulation
granted -
US 11013809
Sustained delivery formulations of risperidone compound
granted -
US 11000520
Buprenorphine dosing regimens
granted -
US 10654842
Dopamine D3 receptor antagonist compounds
granted
Frequently asked questions
What is US patent 9295645?
US 9295645 (Compositions comprising buprenorphine) is held by Indivior UK Limited. Status: granted. Granted Mar 29, 2016. Expires Mar 24, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9295645?
Indivior UK Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 34 pharmaceutical patents for this assignee.
When does US 9295645 expire?
Our index shows an expiration date of Mar 24, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.